RALEIGH, N.C.–(HSMN NewsFeed)–Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ) today reported that the Gastrointestinal Drugs Advisory Committee of the FDA has recommended by a vote of 14 to 4 in favor of the approval of XIFAXAN® (rifaximin) Tablets, 550 m…
Biopharmaceuticals, FDA
Salix Pharmaceuticals, XIFAXAN, rifaximin, hepatic encephalopathy

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy”
Leave a Comment